Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's Ongoing User Fee System Upgrade Limits Payment Options

This article was originally published in The Pink Sheet Daily

Executive Summary

But it comes at a time when there is traditionally a lull in filings of generic drug applications.

You may also be interested in...



GDUFA II: Inspection Information Takes Center Stage

Sponsors say transparency is important as generic drug user fee negotiations move to inspection policy.

PDUFA Negotiations Begin With FDA Seeking Review System Reform

Fee structure changes and process enhancements floated during opening session between industry and agency.

Rare Cancer Development Consortium Moving Toward Target Selection

An upcoming public meeting will include a look at platforms before the first targets are chosen.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS079071

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel